Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLTAGE-2: Nivolumab With Selective Use of Chemoradiotherapy and Surgery in dMMR/MSI-H Rectal Cancer
jRCT2031220484Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab in rectal adenocarcinoma (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 2-year clinical complete response (cCR) rate with nivolumab alone (investigator assessment). Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031220484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220484.